Trials / Completed
CompletedNCT00863850
Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy (Hematologic or Nonhematologic)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bendamustine | Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2010-02-01
- Completion
- 2010-03-01
- First posted
- 2009-03-18
- Last updated
- 2012-04-23
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00863850. Inclusion in this directory is not an endorsement.